CTOR CTOR
Company Profile ↓Company Overview
CTOR (CTOR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -61.89% |
| 6 Months: | -29.28% |
| 3 Months: | -17.97% |
| 1 Month: | +10.56% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)67.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 3.94M | 1.67M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 3.15M | 1.34M |
| Operating Income | - | - | - | -147.92K | -199.55K | -421.45K | - | -268.43K | -4.63M | -6.39M | -7.47M | -4.94M | -5.25M | -28.61M |
| Net Income | -724 | - | - | 611.73K | 616.30K | 157.94K | -4.73M | -4.84M | -4.77M | -6.66M | -7.74M | -5.37M | -5.53M | -26.61M |
| Diluted EPS | - | 0.00 | 0.00 | 0.07 | 0.07 | 0.02 | -0.07 | -0.07 | -0.07 | -0.09 | -0.11 | -0.08 | -0.06 | -0.27 |
| R&D Expense | - | - | - | - | - | - | 1.15M | 1.35M | 1.13M | 1.26M | 3.14M | 938.28K | 1.02M | 1.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | - | 0 | - | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | 4.86M | - | 12.12M | - | 20.57M | 23.52M |
| Operating Income | -10.11K | -4.86M | -138.12K | -12.12M | -1.01M | -20.57M | -23.52M |
| EBITDA | - | -4.86M | - | -12.12M | - | -20.57M | -23.49M |
| Interest Expense | - | - | - | - | - | 0 | 218.03K |
| Pretax Income | - | -4.86M | - | -12.12M | - | -20.57M | -23.70M |
| Tax Provision | - | 576.00K | - | 576.00K | - | 576.00K | 1.06M |
| Net Income | -10.11K | -5.43M | 380.81K | -12.70M | 2.42M | -21.15M | -24.76M |
| Diluted EPS | - | -0.08 | 0.12 | -0.18 | 0.27 | -0.31 | -0.34 |
| R&D Expense | - | - | - | 4.24M | - | 4.93M | 6.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 126.42K | - | 68.19M | 47.73M | 72.62M | 84.37M | 100.94M |
| Total Equity | -10.11K | 36.27M | 345.51K | 25.54M | -1.99M | 46.14M | 44.87M |
| Total Liabilities | - | - | - | 22.20M | - | 38.23M | 56.08M |
| Current Liabilities | 136.53K | - | 31.84K | 21.05M | 2.05M | 32.70M | 49.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -47.97K | -601.30K | 126.35K | -5.49M |
| Investing Cash Flow | -67.32M | -1.32M | -5.00M | -5.75M |
| Financing Cash Flow | 67.66M | 1.66M | 4.87M | 15.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 100.0% | -15.0% | 110.2% | -49.7% | -121.7% | -45.8% | -55.2% |
| ROCE % | 100.0% | - | -0.2% | -45.4% | -1.4% | -39.8% | -45.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTOR
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQj…
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBfb19pMzljR0tOTlRqWkNrSHpNRUUzS2RLdlFWSEVLeEFkQW1FcUlZZl8yV1FBVUtreW9icUw3ZC1IcEVhNVhWOFdtdk1JUUdnRUY2UG5EWGRzbXNJ?oc=5" target="_blank">CTOR Stock Price and Chart — NASDAQ:CTOR</a…
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNWk11SmpsQ0hLcUlhSFFOWHF0LWk4bm9nYXNkUk1FaWpheGNfLTQ4Szl1Q0c3Vk03LVRiWHM3ejBUUV9ULUJRNVg5bFlnRElHc2xYejJjZEtmZ1M2UVA2TmswQ0dTMXVuSnpzNmZRY0FvY0VuZjhSZlBIOWstZ3FkenpXMDJISzBRMkN3VW…
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUlIwM0t2WXdRZzMzTzJtbWZtcVd1ekp5dThaY0hqbHhqdi1ETi05Q0ViUE5SbUZLSE9zckpPZmNaZ1VHT2FUc25qb0NUUHp5WE1hOVBSLUNja3VNdU9mMHNtZmVmZGFudzRKMVFITHpqQkhrVW1ReERYcFNVc2xqMlA2aFZPYmU2Rnl6T3…
CTOR|Citius Oncology Inc|Price:0.677|Chg%:+0.052 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBCWGt4OHFYaUVyMXdIaVBydE1XeHFUUEpjWDZMS1hDcEdpMnRLOVdQNkxENUtaQ2YzUkpZQnlvN2lVd1B6MFo1Y2ctOGdtbUhiZG5PV1hTdVMxcVFrQkh0VHZQeDJRdl9vZE56aklB?oc=5" target="_blank">CTOR|Citius Oncolog…
Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8wT205M19TWGo4WE0zaHFyb1poWTRvV0xPWnZQc3ZkNDF1akN3dkRDRlpBSE9PMnlqLTZzZEpqUjlSMWNDZ2pCOTRSUzNyWVpYRWk5NmNua2w0eTRnUTgwWXdiY3I5Y0dWREVZOXNoRU5TOUJPVDdV?oc=5" target="_blank">Citius …
CTOR — Frequently Asked Questions
What is the current share price of CTOR?
As of 2026-08-05 17:25 PDT, CTOR trades at $0.78 on NASDAQ/NYSE. Its 52-week range is $0.49 to $2.17.
What is the P/E ratio of CTOR?
CTOR trades at a trailing price-to-earnings (P/E) ratio of -2.29.
What is the return on equity (ROE) of CTOR?
CTOR has a return on equity (ROE) of -55.19%. Its return on capital employed (ROCE) is -45.72%.
Is CTOR a good stock to buy?
This page provides a data-driven analysis of CTOR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.